Report Overview

Examines the market for addiction pharmacotherapies currently estimated at US$2 billion but forecast to increase 41% CAGR to US$2.9 billion by 2012. Drivers of growth include increasing global prevalence of alcohol, narcotic, and nicotine dependencies and premarket pharmacotherapies to treat methamphetamine, phencyclidine, and gambling addictions. With over 30 drug candidates in the pipeline for addiction disorders, medical therapies for these highly prevalent difficult-to-treat conditions are on course for dynamic change. This report comments on strategic and commercial issues that may affect current product positioning and discusses key compounds such as naltrexone reformulations, nicotine replacement therapies, and novel vaccine therapies that have the potential to create new market sectors and become high-value products over the next decade. The report also provides insights into forthcoming market dynamics and product sales to 2012 to enable the reader to make assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.